Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer
The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Following the completion of the Human Genome Project in 2003, research in oncology has progressively focused on the sequencing of cancer genomes, with the aim of better understanding the genetic basis of oncogenesis and identifying actionable alterations. The development of next-generation-sequencing (NGS) techniques, commercially available since 2006, allowed for a cost- and time-effective sequencing of tumor DNA, leading to a "genomic era" of cancer research and treatment. NGS provided a significant step forward in Personalized Medicine (PM) by enabling the detection of somatic driver mutations, resistance mechanisms, quantification of mutational burden, germline mutations which settled the foundation of a new approach in cancer care. In this chapter we discuss the history, available techniques and applications of NGS in oncology, with a particular referral to the PM approach and the emerging role of the research field of pharmacogenomics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genome sequencing in microfabricated high-density picolitre reactors
Margulies, M., Egholm, M., Altman, W. E., Attiya, S., Bader, J. S., Bemben, L. A., Berka, J., Braverman, M. S., Chen, Y.-J., Chen, Z., et al. (2005) · Nature · doi:10.1038/nature03959 · Cited by 7,693
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Tomczak, K., Czerwińska, P., & Wiznerowicz, M. (2015) · Współczesna Onkologia · doi:10.5114/wo.2014.47136 · Cited by 3,492
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Microsatellite Instability in Cancer of the Proximal Colon
Thibodeau, S. N., Bren, G., & Schaid, D. (1993) · Science · doi:10.1126/science.8484122 · Cited by 3,130
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays
Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M., & Gilad, Y. (2008) · Genome Research · doi:10.1101/gr.079558.108 · Cited by 2,771
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
The double-strand-break repair model for recombination
Szostak, J. W., Orr-Weaver, T. L., Rothstein, R. J., & Stahl, F. W. (1983) · Cell · doi:10.1016/0092-8674(83)90331-8 · Cited by 2,437
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
A comprehensive catalogue of somatic mutations from a human cancer genome
Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., Varela, I., Lin, M.-L., Ordóñez, G. R., Bignell, G. R., et al. (2010) · Nature · doi:10.1038/nature08658 · Cited by 1,696
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Brca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,169
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Lynch, H. T., Smyrk, T. C., Watson, P., Lanspa, S. J., Lynch, J. F., Lynch, P. M., Cavalieri, R. J., & Boland, C. R. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90368-m · Cited by 1,065
Stem cell transcriptome profiling via massive-scale mRNA sequencing
Cloonan, N., Forrest, A. R. R., Kolle, G., Gardiner, B. B. A., Faulkner, G. J., Brown, M. K., Taylor, D. F., Steptoe, A. L., Wani, S., Bethel, G., et al. (2008) · Nature Methods · doi:10.1038/nmeth.1223 · Cited by 1,035
Nelson, D. R. (2009) · Human Genomics · doi:10.1186/1479-7364-4-1-59 · Cited by 1,014
BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks
Moynahan, M. E., Pierce, A. J., & Jasin, M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00174-5 · Cited by 1,006
SEQC/MAQC-III Consortium (2014) · Nature Biotechnology · doi:10.1038/nbt.2957 · Cited by 983
Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 936
Repair of Strand Breaks by Homologous Recombination
Jasin, M., & Rothstein, R. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012740 · Cited by 887
Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2
Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., Liu, X., Jasin, M., Couch, F. J., & Livingston, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.022 · Cited by 861
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
Jennings, L. J., Arcila, M. E., Corless, C., Kamel-Reid, S., Lubin, I. M., Pfeifer, J., Temple-Smolkin, R. L., Voelkerding, K. V., & Nikiforova, M. N. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.01.011 · Cited by 743
The control of DNA repair by the cell cycle
Hustedt, N., & Durocher, D. (2017) · Nature Cell Biology · doi:10.1038/ncb3452 · Cited by 738
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 648
IntOGen-mutations identifies cancer drivers across tumor types
Gonzalez-Perez, A., Perez-Llamas, C., Deu-Pons, J., Tamborero, D., Schroeder, M. P., Jene-Sanz, A., Santos, A., & Lopez-Bigas, N. (2013) · Nature Methods · doi:10.1038/nmeth.2642 · Cited by 586
Schiavon, G., Hrebien, S., Garcia-Murillas, I., Cutts, R. J., Pearson, A., Tarazona, N., Fenwick, K., Kozarewa, I., Lopez-Knowles, E., Ribas, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7551 · Cited by 575
Chandarlapaty, S., Chen, D., He, W., Sung, P., Samoila, A., You, D., Bhatt, T., Patel, P., Voi, M., Gnant, M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1279 · Cited by 494
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481
André, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., Lacroix-Triki, M., Lacroix, L., Cohen, P., Gentien, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70611-9 · Cited by 404
Moderne Probleme der Humangenetik
Vogel, F. (1959) · Ergebnisse der Inneren Medizin und Kinderheilkunde · doi:10.1007/978-3-642-94744-5_2 · Cited by 397
Reliable Identification of Genomic Variants from RNA-Seq Data
Piskol, R., Ramaswami, G., & Li, J. B. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.08.008 · Cited by 381
Genetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., Kharasch, E. D., & Skaar, T. C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.287 · Cited by 371
Hainsworth, J. D., Rubin, M. S., Spigel, D. R., Boccia, R. V., Raby, S., Quinn, R., & Greco, F. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3755 · Cited by 362
Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11579 · Cited by 309
Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T., Novello, S., O'Byrne, K., Stahel, R., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 298
Human Genome Project: Twenty-five years of big biology
Green, E. D., Watson, J. D., & Collins, F. S. (2015) · Nature · doi:10.1038/526029a · Cited by 279
Lebofsky, R., Decraene, C., Bernard, V., Kamal, M., Blin, A., Leroy, Q., Rio Frio, T., Pierron, G., Callens, C., Bieche, I., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.12.003 · Cited by 269
Settling the score: variant prioritization and Mendelian disease
Eilbeck, K., Quinlan, A., & Yandell, M. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.52 · Cited by 228
Mandelker, D., Schmidt, R. J., Ankala, A., McDonald Gibson, K., Bowser, M., Sharma, H., Duffy, E., Hegde, M., Santani, A., Lebo, M., et al. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.58 · Cited by 224
Shu, Y., Wu, X., Tong, X., Wang, X., Chang, Z., Mao, Y., Chen, X., Sun, J., Wang, Z., Hong, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00520-1 · Cited by 223
Raphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 218
Expanding the computational toolbox for mining cancer genomes
Ding, L., Wendl, M. C., McMichael, J. F., & Raphael, B. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3767 · Cited by 185
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0554-cp · Cited by 172
Computational approaches to identify functional genetic variants in cancer genomes
the International Cancer Genome Consortium Mutation Pathways and Consequences Subgroup of the Bioinformatics Analyses Working Group (2013) · Nature Methods · doi:10.1038/nmeth.2562 · Cited by 171
Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?
Ignatiadis, M., & Dawson, S.-J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu480 · Cited by 158
The MINDACT trial: The first prospective clinical validation of a genomic tool
Cardoso, F., Piccart, M. J., Veer, L. V., et al. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.10.004 · Cited by 145
Precision medicine: the foundation of future cancer therapeutics
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0016-z · Cited by 128
Sequencing the CYP2D6 Gene: From Variant Allele Discovery to Clinical Pharmacogenetic Testing
Yang, Y., Botton, M. R., Scott, E. R., & Scott, S. A. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0033 · Cited by 124
Emerging Understanding of Multiscale Tumor Heterogeneity
Gerdes, M. J., Sood, A., Sevinsky, C., Pris, A. D., Zavodszky, M. I., & Ginty, F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00366 · Cited by 118
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
Varghese, A. M., Arora, A., Capanu, M., Camacho, N., Won, H. H., Zehir, A., Gao, J., Chakravarty, D., Schultz, N. D., Klimstra, D. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx545 · Cited by 117
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Yang, M., Forbes, M. E., Bitting, R. L., O’Neill, S. S., Chou, P. C., Topaloĝlu, Ü., Miller, L. D., Hawkins, G. A., Grant, S. C., DeYoung, B. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx766 · Cited by 109
Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00082-6 · Cited by 107
Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor
Salahshor, S., Kressner, U., Fischer, H., Lindmark, G., Glimelius, B., Påhlman, L., & Lindblom, A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690676 · Cited by 103
Su, D., Zhang, D., Chen, K., Lu, J., Wu, J., Cao, X., Ying, L., Jin, Q., Ye, Y., Xie, Z., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0591-4 · Cited by 102
Consensus on precision medicine for metastatic cancers: a report from the MAP conference
Swanton, C., Soria, J., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S.-Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw192 · Cited by 98
Prognostic and predictive significance of MSI in stages II/III colon cancer
Saridaki, Z. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6809 · Cited by 86
Chronic Myelogenous Leukemia, Version 1.2014
O'Brien, S. M., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., DeAngelo, D. J., Deininger, M. W., Devine, S. M., Fathi, A. T., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0157 · Cited by 83
Dihydropyrimidinase deficiency: Phenotype, genotype and structural consequences in 17 patients
Kuilenburg, A. B. P., Dobritzsch, D., Meijer, J., Meinsma, R., Benoist, J., Assmann, B. E., Schubert‐Bast, S., Hoffmann, G. F., Durán, M., de Vries, M. C., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.03.013 · Cited by 80
Wang, R., Li, X., Zhang, H., Wang, K., & He, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20608 · Cited by 68
O'Kane, G. M., Connor, A. A., & Gallinger, S. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.007 · Cited by 67
Applicability of Next Generation Sequencing Technology in Microsatellite Instability Testing
Gan, C., Love, C., Beshay, V., Macrae, F., Fox, S., Waring, P., & Taylor, G. (2015) · Genes · doi:10.3390/genes6010046 · Cited by 50
Cancer heterogeneity: origins and implications for genetic association studies
Urbach, D., Lupien, M., Karagas, M. R., & Moore, J. H. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.07.001 · Cited by 47
Gao, J., Wu, H., Shi, X., Huo, Z., Zhang, J., & Liang, Z. (2016) · Clinical Laboratory · doi:10.7754/clin.lab.2015.150837 · Cited by 47
Jazwinska-Tarnawska, E. K., Orzechowska-Juzwenko, K., Niewiński, P., Rzemisławska, Z., Loboz-Grudzien, K., Dmochowska-Perz, M., & Sławin, J. (2001) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp39288 · Cited by 35
Gambino, G., Tancredi, M., Falaschi, E., Aretini, P., & Caligo, M. A. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2103 · Cited by 22
Next Generation Sequencing in Pharmacogenomics
Demkow, U. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801739-5.00011-8 · Cited by 20
Re, M. D., Quaquarini, E., Sottotetti, F., Michelucci, A., Palumbo, R., Simi, P., Danesi, R., & Bernardo, A. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.146 · Cited by 20
Brinkmann, K., Enderle, D., Koestler, T., Bentink, S., Emenegger, J., Spiel, A., Mueller, R., O’Neill, V., Skog, J., & Noerholm, M. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-545 · Cited by 15
Martínez‐Sellés, M., Castillo, I., Montenegro, P., Martín, M. L., Almendral, J. M., & Sanjurjo‐Sáez, M. (2005) · Revista Española de Cardiología · doi:10.1157/13076423 · Cited by 12
Martínez‐Sellés, M., Castillo, I., Montenegro, P., Martín, M. L., Almendral, J. M., & Sanjurjo‐Sáez, M. (2005) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(06)60256-9 · Cited by 9
Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer
Esposito, A., Criscitiello, C., & Curigliano, G. (2015) · JNCI Monographs · doi:10.1093/jncimonographs/lgv012 · Cited by 9
Self-citationHIM and the path to personalized medicine.
Mendoza, M. C. B. (2011) · PubMed · Cited by 5
Research works printed but not linked: 2
- Oxford Nanopore Technologies. Available at: https://nanoporetech.com/ . Accessed: 15 Apr 2018
- Le DT et al (2017) HHS Public Access 357:409–413
Cited by
Clinical application and detection techniques of liquid biopsy in gastric cancer
Ma, S., Zhou, M., Xu, Y., Gu, X., Zou, M., Abudushalamu, G., Yao, Y., Fan, X., & Wu, G. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01715-z · Cited by 190
“Furthermore, although NGS technology can improve detection sensitivity through enrichment and amplification, it also introduces issues such as gene information mismatches, incomplete detection information, and false positives [224].”
BackgroundMatsuoka, T., & Yashiro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115880 · Cited by 83
“The capacity to predict the efficacy of a patient with cancer on a particular treatment regimen is the elaborate goal of precision oncology [67].”
BackgroundUsing the Biopsychosocial Model to Guide Patient-Centered Neurological Treatments
Saxena, A., Paredes-Echeverri, S., Michaelis, R., Popkirov, S., & Perez, D. L. (2022) · Seminars in Neurology · doi:10.1055/s-0041-1742145 · Cited by 53
Metadata
- Authors
- Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Duso, B. A., & Curigliano, G.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Curigliano, Giuseppe
- ORCID
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer International Publishing
- Published
- 2019
- Volume
- 1168
- Pages
- 9-30
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W3144501467
- Cited by
- 246
- References
- 97
- Citations by year
- 2026: 17 · 2025: 33 · 2024: 53 · 2023: 46 · 2022: 43 · 2021: 33 · 2020: 20 · 2019: 1
- FWCI
- 29.61
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- next-generation sequencing, pharmacogenomics, personalized medicine, cancer genomics, somatic driver mutations, tumor mutational burden, germline mutations, drug resistance mechanisms, actionable alterations
- MeSH terms
- Humans, Neoplasms, Pharmacogenetics, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.